iSpecimen Inc (ISPC) FinancialsISPCiSpecimen Inc

iSpecimen Inc (ISPC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specimens – contracts with customers, accounting for 86.2% of total sales, equivalent to $134.41K. Another important revenue stream is Shipping and other. Understanding this composition is critical for investors evaluating how ISPC navigates market cycles within the Software industry.

Evaluating the bottom line, iSpecimen Inc maintains a gross margin of 45.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -897.06%, while the net margin is -896.94%. These profitability ratios, combined with a Return on Equity (ROE) of -968.47%, provide a clear picture of how effectively ISPC converts its operational activities into shareholder value.

In the context of the broader market, ISPC competes directly with industry leaders such as GWAV and MGN. With a market capitalization of $4.26M, it holds a leading position in the sector. When comparing efficiency, ISPC's gross margin of 45.18% stands against GWAV's 24.03% and MGN's 1.74%. Such benchmarking helps identify whether iSpecimen Inc is trading at a premium or discount relative to its financial performance.

The financial performance of iSpecimen Inc shows a troubling trend with consistent net losses over recent quarters, including a net income loss of -1,362,811 USD in Q2 2026. The gross margin has varied, with a recent figure of 45.18%, but the overall revenue has been declining sharply, with total revenue dropping from 2,661,936 USD in Q3 2024 to just 151,940 USD in Q2 2026.